Home > Publications Database > Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. > print

001     155714
005     20240404115649.0
024 7 _ |a 10.1002/acn3.51402
|2 doi
024 7 _ |a pmid:34129723
|2 pmid
024 7 _ |a pmc:PMC8283172
|2 pmc
024 7 _ |a altmetric:107698798
|2 altmetric
037 _ _ |a DZNE-2021-00882
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bergström, Sofia
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease.
260 _ _ |a Chichester [u.a.]
|c 2021
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712138510_27005
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Decreased amyloid beta (Aβ) 42 together with increased tau and phospho-tau in cerebrospinal fluid (CSF) is indicative of Alzheimer's disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.We utilized an antibody-based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP-regulated phosphoprotein 21 (ARPP21), growth-associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aquaporin 4: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnosis
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a GAP-43 Protein: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Nerve Tissue Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Phosphoproteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Protein Array Analysis: methods
|2 MeSH
650 _ 2 |a beta-Synuclein: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
700 1 _ |a Remnestål, Julia
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Yousef, Jamil
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Olofsson, Jennie
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Markaki, Ioanna
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Carvalho, Stephanie
|b 5
700 1 _ |a Corvol, Jean-Christophe
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Kultima, Kim
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Kilander, Lena
|b 8
700 1 _ |a Löwenmark, Malin
|b 9
700 1 _ |a Ingelsson, Martin
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Blennow, Kaj
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Zetterberg, Henrik
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Nellgård, Bengt
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 14
|u dzne
700 1 _ |a Heneka, Michael
|0 P:(DE-2719)2000008
|b 15
|u dzne
700 1 _ |a Bosch, Beatriz
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Sanchez-Valle, Raquel
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Månberg, Anna
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Svenningsson, Per
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Nilsson, Peter
|0 P:(DE-HGF)0
|b 20
773 _ _ |a 10.1002/acn3.51402
|g Vol. 8, no. 7, p. 1456 - 1470
|0 PERI:(DE-600)2740696-9
|n 7
|p 1456 - 1470
|t Annals of Clinical and Translational Neurology
|v 8
|y 2021
|x 2328-9503
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/155714/files/DZNE-2021-00882.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/155714/files/DZNE-2021-00882.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:155714
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810593
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)2000008
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN CLIN TRANSL NEUR : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-04-16T15:13:11Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-04-16T15:13:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-02
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ANN CLIN TRANSL NEUR : 2021
|d 2022-11-09
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-02
920 1 _ |0 I:(DE-2719)1011301
|k Biomarker
|l Interventional Trials and Biomarkers in Neurodegenerative Diseases
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011301
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21